Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
Moderna’s flu and COVID-19 combination vaccine recently delivered positive results in a PIII clinical trial. Chief Medical Affairs Officer Francesca Ceddia in a Tokyo interview touted the strong immune response observed with the jab in the study, describing it as…
To read the full story
Related Article
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
- Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec
April 17, 2024
- Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief
April 11, 2024
BUSINESS
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…